Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors.

Position Summary:

Reporting to the Chief Scientific Officer, the Vice President/Senior Director of Nonclinical Drug Safety and Toxicology is a key position within the R&D leadership team and will lead nonclinical aspects of all the company’s pipeline programs. As the most senior toxicology expert within the organization, the VP will be responsible for providing strategic and operational leadership for the toxicology group across the portfolio of discovery, early development, and late development programs. The Non-Clinical Safety and Toxicology leader will partner cross-functionally across therapeutic areas with colleagues in drug discovery, translational, and clinical development functions, ensuring toxicology and nonclinical safety data is shared and communicated transparently and plays a role in informing strategy at all stages of each program’s development.

Key Responsibilities:

Areas of specific responsibility and attention will include the following:

Create a long-term global toxicology strategy in alignment with the company’s vision and objectives, including multi-year scientific and operational plans
Lead scientific direction for global regulatory toxicology including safety pharmacology
Lead scientific direction for safety assessments of discovery and early development programs, aligning with program objectives and regulatory strategies
Oversee toxicology findings and provide advice to project teams and senior management on potential impact of results on program goals and probability of success
Collaboratively design and implement external toxicity studies (in vitro and in vivo) required for lead optimization, and development candidate selection
Develop strategy, plan and budget to effectively manage regulatory toxicity studies (in vitro and in vivo) required for IND and NDA submissions, including general toxicity, juvenile toxicity, genotoxicity, safety pharmacology, reproductive and developmental, and carcinogenicity studies
Work with internal R&D leaders and external parties including development partners, consultants, CROs and approved vendors based on a balance of quality, timeliness, and cost
Develop and manage all timelines related to this function
Identify and engage experts in the field of toxicology (e.g., consultants) to interpret study results and make recommendations, as needed
Communicate toxicity study results to discovery program and development teams, and to the company’s executive management and Board of Directors, as needed
Actively participate in regulatory meetings
Other duties as assigned

Qualifications:

PhD in toxicology or related discipline with at least 15 years of experience, (an equivalent combination of experience and education may be considered)
Preferred 10 years of experience managing and developing a drug safety/toxicology team
DABT certification strongly preferred
Experience in defining and implementing scientifically relevant and compliant nonclinical toxicology strategies and contingency plans addressing both theoretical and identified nonclinical safety issues
Collaborative mindset capable of excelling within multi-discipline discovery and development teams
Proven track record of interfacing with global regulatory authorities, and the design and interpretation of safety studies for regulatory submissions, including INDs and NDAs
Deep knowledge of FDA and EMA requirements and guidance for nonclinical safety submissions
Strong communication (written and oral) and interpersonal skills with an ability to effectively function within a matrixed environment

Salary Range

$293,000 - $358,000 USD

This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

About the company

Remix Therapeutics develops medicines for rare diseases with a focus on targeted mRNA degradation. Its lead product REM 422 is an oral small molecule that degrades messenger RNA to stop production of disease-causing proteins. REM 422 is in Phase 1 trials for Adenoid Cystic Carcinoma and Acute Myeloid Leukemia, with FDA Orphan Drug Designation to support development. Remix funds its R&D through grants and partnerships, aiming to bring safe, effective therapies to patients and expand its portfolio.

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$224.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Get referred to Remix Therapeutics

See people who can refer or advise you

Simplify's Take

What believers are saying

September 9, 2026 hired Nicole Sweeny, strengthening launch readiness and commercialization.
September 2, 2026 amended merger improved tax efficiency and execution mechanics.
ASCO 2026 oral presentation and 2027 readouts keep clinical momentum visible.

What critics are saying

The June 2026 merger can still fail before the December 24, 2026 outside date.
REM-422 remains the only meaningful value driver; Phase 2 failure destroys the story.
September 2026 financing shrank to roughly $70 million, increasing dilution pressure.

What makes Remix Therapeutics unique

RM-422 is an oral small molecule reprogramming RNA processing, not a biologic.
MYB targeting attacks a historically undruggable cancer driver in adenoid cystic carcinoma.
Remaster pairs data science and chemistry to find orally available gene-expression modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-5%

2 year growth

-1%

GlobeNewswire

Oct 6th, 2026

Remix therapeutics(tm) appoints Michael Landsittel to Board of Directors.

Remix therapeutics(tm) appoints Michael Landsittel to Board of Directors. WATERTOWN, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) - Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Michael Landsittel to its Board of Directors. "We are delighted to welcome Michael to the Remix Board of Directors," said Pete Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics. "His proven track record of building and scaling innovative biotechnology companies, combined with his strategic perspective and broad industry expertise, will be invaluable as we continue advancing our RNA processing platform and pipeline and prepare to operate as a public company. We look forward to leveraging his experience as we execute on our strategy and work to deliver transformative medicines for patients." Mr. Landsittel is a seasoned biotechnology executive with over 20 years of experience spanning strategic finance, corporate and business development, investor relations and organizational leadership. Most recently, Mr. Landsittel served as Chief Financial Officer at Blueprint Medicines Corporation, where he helped guide the company through its $9.1 billion acquisition by Sanofi in 2025. During his more than decade-long tenure at Blueprint, he led efforts to raise approximately $4 billion in capital through a variety of transactions and helped lead the company's transformation into a commercial-stage biotechnology company with the launch of AYVAKIT(R)(avapritinib). Prior to joining Blueprint, Mr. Landsittel served as Senior Director of Finance at Algeta ASA through its acquisition by Bayer. Before that, he held financial planning, business development and corporate strategy roles at Infinity Pharmaceuticals and Genzyme Corporation. Mr. Landsittel currently serves on the Board of Directors at Damora Therapeutics. He received an M.B.A. from the Tuck School of Business at Dartmouth College and a B.B.A. from the University of Michigan. "I am thrilled to join the Board of Directors at Remix at such an exciting time in the Company's evolution," said Mr. Landsittel. "Remix has built a strong foundation through its innovative science in RNA-targeted medicines, talented team and disciplined execution. I look forward to working alongside the Board and management team to support Remix in its next phase of growth and contribute to the company's mission of translating cutting-edge science into meaningful medicines for patients with significant unmet medical need." About Remix Therapeutics Remix Therapeutics is a clinical stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster(TM) technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs: the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC) and a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).

Associated Press

Sep 9th, 2026

Remix Therapeutics appoints Nicole Sweeny as chief commercial officer

Remix Therapeutics has appointed Nicole Sweeny as Chief Commercial Officer. The clinical-stage biotechnology company develops small molecule therapies to modulate RNA processing. Sweeny brings over 20 years of commercial strategy and leadership experience in rare disease and specialty biopharma. She previously served as Chief Commercial Officer at KalVista Pharmaceuticals, where she built the company's commercial organisation through its acquisition by Chiesi Group. She also held the same role at Praxis Precision Medicines. Remix's REMaster technology platform uses data science and chemistry to identify orally administered compounds that modulate gene expression. The company is currently evaluating REM-422, its investigational small molecule, in Phase 1/2 clinical studies for adenoid cystic carcinoma and a Phase 1 study in acute myeloid leukaemia and high-risk myelodysplastic syndrome.

GlobeNewswire

Sep 9th, 2026

Remix Therapeutics appoints Nicole Sweeny as Chief Commercial Officer.

Remix Therapeutics appoints Nicole Sweeny as Chief Commercial Officer. Accomplished industry executive to lead commercial strategy and launch readiness. WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) - Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Nicole Sweeny as Chief Commercial Officer. "As we continue to advance our pipeline and build the foundation for long-term growth, Nicole's proven track record of commercial leadership, strategic vision, and patient-centric approach make her an outstanding addition to our executive team," said Peter Smith, Ph.D., Co-Founder and CEO of Remix. "Nicole has successfully guided organizations through critical stages of growth and commercialization, and her experience will be invaluable as we work to bring transformative medicines to patients." "Remix has built a truly differentiated platform with the potential to unlock a new class of medicines by targeting RNA processing," said Ms. Sweeny. "I am excited to join the team at such an important time in the company's evolution. I look forward to working alongside my colleagues to ensure that, as our programs advance, we remain focused on delivering meaningful therapies to patients while building the capabilities needed to support future launches and sustained growth." Ms. Sweeny brings more than 20 years of commercial strategy and leadership experience launching innovative therapies across rare disease and specialty biopharma. Prior to joining Remix, she served as Chief Commercial Officer at KalVista Pharmaceuticals, where she built and led the company's commercial organization and launch readiness efforts through its acquisition by Chiesi Group. Before that, she served as Chief Commercial Officer at Praxis Precision Medicines. Earlier in her career, Ms. Sweeny was a Franchise Head in US Rare Diseases at Takeda Pharmaceuticals. Before Takeda, she held positions of increasing responsibility at Shire Pharmaceuticals in marketing, sales and product strategy. Ms. Sweeny received a B.S. in Marketing from the Carroll School of Management at Boston College. About Remix Therapeutics Remix Therapeutics is a clinical stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster(TM) technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs: the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC) and a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).

Alabama Business Reporter

Sep 1st, 2026

Remix Therapeutics to participate in upcoming investor conferences.

Remix Therapeutics to participate in upcoming investor conferences. WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) - Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that management will participate in the following upcoming investor conferences: * Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 21st Annual Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 10:15 a.m. ET in Boston. * Remix management will participate in 1x1 meetings at the Cantor Global Healthcare Conference 2026 on Wednesday, September 9, 2026, in New York City. About Remix Therapeutics Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster(TM) technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, an RNA processing modulator in oncology, now being evaluated in a Phase 1/2 clinical study to treat acute myeloid leukemia (AML), and a Phase 1 clinical study in high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC). Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Alabama Business Reporter do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Pharma Journalist

Jun 25th, 2026

Remix Therapeutics to merge with Passage Bio.

Remix Therapeutics to merge with Passage Bio. On Jun 25, 2026 Remix Therapeutics and Passage Bio have agreed to merge in an all-stock transaction, creating a combined biotechnology company focused on advancing RNA-targeted therapies for cancer and other serious diseases. The deal is backed by a new $100 million private financing, providing the merged company with the resources needed to advance its clinical pipeline through several key development milestones. Following the completion of the transaction, the combined company will operate under the name Remix Therapeutics, Inc. and is expected to trade on the Nasdaq stock exchange under the ticker symbol "RMTX." Alongside the merger announcement, Remix revealed that it has secured commitments for an oversubscribed private placement financing led by Decheng Capital, with participation from Lynx1 Capital Management, Forge Life Science Partners, existing investors, and several other institutional investment firms. The financing is expected to close immediately before the merger is finalized. The combined company expects its cash position, including proceeds from the private placement, to fund operations into 2028. The funding is intended to support several important clinical milestones, including data from the registrational Phase 2 trial of REM-422 in Adenoid Cystic Carcinoma (ACC), results from a Phase 1 trial evaluating the therapy in Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS), as well as continued investment in Remix's discovery pipeline. The merger strengthens Remix's position as it develops a new class of small-molecule medicines designed to modulate RNA processing. Unlike conventional therapies that target proteins directly, Remix's platform focuses on controlling how RNA is processed inside cells, offering the potential to treat diseases driven by genetic abnormalities that have historically been difficult to target with existing drugs. At the center of the company's pipeline is REM-422, an orally administered mRNA degrader that targets MYB, a transcription factor involved in several cancers. MYB has long been considered one of the most challenging cancer targets for drug developers, making REM-422 a potentially significant advance if ongoing clinical studies continue to produce positive results. Peter Smith, Ph.D., co-founder and Chief Executive Officer of Remix Therapeutics, described the merger as a transformative milestone for the company. He said the transaction provides the financial strength and operational support needed to accelerate the development of RNA-targeted medicines while expanding the company's proprietary platform. Smith added that the financing and merger position Remix to rapidly advance REM-422 and other pipeline candidates, with the goal of delivering innovative treatment options for patients with cancers that currently have limited therapeutic choices. For Passage Bio, the agreement follows an extensive review of strategic alternatives aimed at maximizing shareholder value. President and Chief Executive Officer Dr. Will Chou said Remix emerged as the ideal partner because of its differentiated RNA processing technology and encouraging early clinical data for REM-422 in adenoid cystic carcinoma. Chou noted that the ongoing registrational study, combined with the company's experienced leadership team, offers Passage Bio shareholders the opportunity to participate in a clinical-stage biotechnology company with a clearly defined path toward pivotal clinical data. The merger reflects growing investor confidence in RNA-based drug development, an area that has attracted increasing attention across the biotechnology industry. By combining Passage Bio's public company infrastructure with Remix's clinical-stage pipeline and fresh capital, the new organization aims to accelerate the development of innovative RNA-targeted therapies and expand treatment options for patients with difficult-to-treat cancers.

Remix Therapeutics

Vice President/Senior Director - Nonclinical Drug Safety & Toxicology

About the job